Consensus Recommendations for Systematic Evaluation of Drug–Drug Interaction Evidence for Clinical Decision Support
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BackgroundHealthcare organizations, compendia, and drug knowledgebase vendors use varying methods to evaluate and synthesize evidence on drug–drug interactions (DDIs). This situation has a negative effect on electronic prescribing and medication information systems that warn clinicians of potentially harmful medication combinations.ObjectiveThe aim of this study was to provide recommendations for systematic evaluation of evidence for DDIs from the scientific literature, drug product labeling, and regulatory documents.MethodsA conference series was conducted to develop a structured process to improve the quality of DDI alerting systems. Three expert workgroups were assembled to address the goals of the conference. The Evidence Workgroup consisted of 18 individuals with expertise in pharmacology, drug information, biomedical informatics, and clinical decision support. Workgroup members met via webinar 12 times from January 2013 to February 2014. Two in-person meetings were conducted in May and September 2013 to reach consensus on recommendations.ResultsWe developed expert consensus answers to the following three key questions. (i) What is the best approach to evaluate DDI evidence? (ii) What evidence is required for a DDI to be applicable to an entire class of drugs? (iii) How should a structured evaluation process be vetted and validated?ConclusionEvidence-based decision support for DDIs requires consistent application of transparent and systematic methods to evaluate the evidence. Drug compendia and clinical decision support systems in which these recommendations are implemented should be able to provide higher-quality information about DDIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914 · cited 1×
“DIPS was developed to address the limitations of previous assessment instruments, such as the Naranjo scale [28], that failed to evaluate causality associated with concomitant medications.”
What is ‘quality of evidence’ and why is it important to clinicians?
Guyatt, G. H., Oxman, A. D., Kunz, R., Vist, G. E., Falck-Ytter, Y., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39490.551019.be · Cited by 3,250
Systematic overview of warfarin and its drug and food interactions
Holbrook, A. M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1095 · Cited by 1,160
Overriding of Drug Safety Alerts in Computerized Physician Order Entry
van der Sijs, H., Aarts, J., Vulto, A., & Berg, M. (2006) · Journal of the American Medical Informatics Association · doi:10.1197/jamia.m1809 · Cited by 1,117
Preventing Medication Errors: Quality Chasm Series
(2007) · doi:10.17226/11623 · Cited by 829
Kesselheim, A. S., Cresswell, K., Phansalkar, S., Bates, D. W., & Sheikh, A. (2011) · Health Affairs · doi:10.1377/hlthaff.2010.1111 · Cited by 277 · cited 3×
“There are no guidelines or standards for determining clinical relevance of interactions via consistent systematic evaluation or classification [9, 21].”
Anglin, R., Yuan, Y., Moayyedi, P., Tse, F., Armstrong, D., & Leontiadis, G. I. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.82 · Cited by 234 · cited 2×
“, elderly, previous GI bleed) and 645 (95 % CI 387–1,152) low-risk patients need to be treated with the SSRI and NSAID combination to cause one upper-GI bleed [47].”
High-priority drug–drug interactions for use in electronic health records
Phansalkar, S., Desai, A. A., Bell, D., Yoshida, E., Doole, J., Czochanski, M., Middleton, B., & Bates, D. W. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000612 · Cited by 134 · cited 2×
“We recommend evaluating any new assessment tools using a subset of 15 ‘high-priority’ DDIs (drug pairs which should always generate an alert) approved by a panel of experts commissioned by the US ONC [63].”
MethodORCA: OpeRational ClassificAtion of Drug Interactions
Hansten, P. D., Horn, J. R., & Hazlet, T. K. (2001) · Journal of the American Pharmaceutical Association (1996) · doi:10.1016/s1086-5802(16)31244-x · Cited by 98 · cited 3×
“, dosage adjustment, monitoring strategies, and therapeutic alternatives) [22, 48].”
Self-citation
Cited by
Edrees, H., Amato, M. G., Wong, A., Seger, D. L., & Bates, D. W. (2020) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocaa034 · Cited by 64
Horn, J., & Ueng, S. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019863419 · Cited by 26
Self-citationIntroduction to Drug Safety and Pharmacovigilance
Jose, J., Cox, A. R., & Bate, A. (2024) · Principles and Practice of Pharmacovigilance and Drug Safety · doi:10.1007/978-3-031-51089-2_1 · Cited by 3
Spanakis, M., Alon-Ellenbogen, D., Ioannou, P., & Spernovasilis, N. (2023) · Pharmacy · doi:10.3390/pharmacy11040130 · Cited by 3
Metadata
- Authors
- Scheife, R. T., Hines, L. E., Boyce, R. D., Chung, S. P., Momper, J. D., Sommer, C. D., Abernethy, D. R., Horn, J. R., Sklar, S. J., Wong, S. K., Jones, G., Brown, M. L., Grizzle, A. J., Comes, S., Wilkins, T. L., Borst, C., Wittie, M. A., & Malone, D. C.
- Venue
- Drug Safety
- Published
- 2015-01-03
- Volume
- 38
- Issue
- 2
- Pages
- 197-206
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- OpenAlex
- W1985995385
- Cited by
- 132
- References
- 11
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.